Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

Author:

Schoenberg Paige1,Edwards O. Winslow1,Merrill Leland2,Martinez Cristian Acero1,Stephenson Rob2ORCID,Sullivan Patrick S.1ORCID,Jones Jeb1ORCID

Affiliation:

1. Department of Epidemiology Emory University Atlanta Georgia USA

2. Department of Systems Populations and Leadership School of Nursing and The Center for Sexuality and Health Disparities, University of Michigan Ann Arbor Michigan USA

Abstract

AbstractIntroductionLong‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.MethodsWe conducted an online, cross‐sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI‐PrEP‐related outcomes and key demographic and behavioural characteristics.ResultsOverall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non‐binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non‐Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non‐Hispanic White participants.ConclusionsWillingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non‐Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.

Funder

National Institute of Nursing Research

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference25 articles.

1. FDA approves first injectable treatment for HIV pre‐exposure prevention.U.S. Food and Drug Administration;2021.

2. Centers for Disease Control and Prevention.Preexposure prophylaxis for the prevention of HIV infection in the United States –2021 update clinical practice guideline.2021. Accessed April 18 2022.https://www.cdc.gov/hiv/pdf/risk/prep/cdc‐hiv‐prep‐guidelines‐2021.pdf

3. Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men

4. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

5. Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3